The new class of antidiabetic drugs Dapagliflozin (DAPA) is a member of sodium-glucose cotransporter-2 (SGLT-2) inhibitors showing promising benefits on DM individuals with CVD (78). The gene discussed is SLC5A2; the disease is diabetes mellitus.